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Abstract
Background: Glioblastoma multiforme is the most lethal brain tumor with limited therapeutic options. Antigens expressed
on the surface of malignant cells are potential targets for antibody-mediated gene/drug delivery.
Principal Findings: In this study, we investigated the ability of genetically modified human mesenchymal stem cells (hMSCs)
expressing a single-chain antibody (scFv) on their surface against a tumor specific antigen, EGFRvIII, to enhance the therapy
of EGFRvIII expressing glioma cells in vivo. The growth of U87-EGFRvIII was specifically delayed in co-culture with hMSC-
scFvEGFRvIII. A significant down-regulation was observed in the expression of pAkt in EGFRvIII expressing glioma cells upon
culture with hMSC-scFvEGFRvIII vs. controls as well as in EGFRvIII expressing glioma cells from brain tumors co-injected with
hMSC-scFvEGFRvIII in vivo. hMSC expressing scFvEGFRvIII also demonstrated several fold enhanced retention in EGFRvIII
expressing flank and intracranial glioma xenografts vs. control hMSCs. The growth of U87-EGFRvIII flank xenografts was
inhibited by 50% in the presence of hMSC-scFvEGFRvIII (p,0.05). Moreover, animals co-injected with U87-EGFRvIII and
hMSC-scFvEGFRvIII intracranially showed significantly improved survival compared to animals injected with U87-EGFRvIII
glioma cells alone or with control hMSCs. This survival was further improved when the same animals received an additional
dosage of hMSC-scFvEGFRvIII two weeks after initial tumor implantation. Of note, EGFRvIII expressing brain tumors co-
injected with hMSCs had a lower density of CD31 expressing blood vessels in comparison with control tumors, suggesting a
possible role in tumor angiogenesis.
Conclusions/Significance: The results presented in this study illustrate that genetically modified MSCs may function as a
novel therapeutic vehicle for malignant brain tumors.
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Introduction
Malignant gliomas remain a challenge in neuro-oncology.
Complete surgical resection is virtually impossible due their
diffusely infiltrative nature and systemic therapy is limited due to
the presence of the blood brain barrier (BBB). These obstacles
have prompted the generation of innovative strategies to tackle
high-grade brain tumors. Among such new strategies is the
development of therapies that target specific cell populations and
increase therapeutic efficacy without harming normal surrounding
cells. Tumor specific antigens which are uniquely expressed by
glioma cells but not by normal brain are excellent candidates for
targeted therapies.
EGFR over-expression is one of the most common genetic
alteration in primary glioblastoma multiforme (GBM) with a
frequency of approximately 40% [1–4]. Along with amplification
of the EGFR gene, there are also mutations. The most common
mutation is the EGFRvIII, which is not seen in normal tissue but
observed in 20–30% of patients with GBM [4–8]. Moreover, in
patients where EGFR gene amplification is confirmed, the
proportion of EGFRvIII increases up to 60% [9–11]. EGFRvIII
is a truncated form of EGFR that does not bind a ligand and is
constitutively active. It is established that the presence of this
variant enhances the aggressiveness of gliomas via several
mechanisms [4,12–18].
The frequent expression of EGFRvIII in human cancers but not in
normal tissues makes it a promising target for therapeutic applications.
Examples of such therapies include tyrosine kinase inhibitors and
monoclonal antibodies [4]. There have been several monoclonal
antibodies (mAb) developed to target EGFR with cross reactivity to
EGFRvIII. Patel et al., showed that a mAb, cetuximab (c225),
successfully targets and binds to U87MG cells expressing EGFRvIII.
This binding led to cetuximab-EGFRvIII complex internalization and
a subsequent reduction in phosphorylated EGFRvIII in transfected
cells. Also, the authors found that treatment of U87-EGFRvIII cells
with cetuximab resulted in a 40–50% reduction in cell proliferation
[19]. Clinical trials have been less promising. Recently, Neyns et al.,
conducted a phase II study using intravenous cetuximab to treat
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have limited effect on disease progression and survival time [20].
EGFRvIII specific monoclonal antibodies have also been developed.
Sampson and co-authors generated Y10, an antibody specific for
EGFRvIII. They showed that Y10 was effective against EGFRvIII-
expressing B16 melanoma in the brain. Specifically, intratumoral
injection improved survival by 286% [21]. Mishima et al., tested
efficacy of another anti-EGFRvIII antibody, mAb 806, in mice with
intracranial xenografts. These authors found that after systemic
treatment with mAb 806, mice with EGFRvIII expressing tumors
(e.g. U87-EGFRvIII) had a 61.5% increase in median survival
compared to controls [22]. Despite these encouraging results,
EGFRvIII tumors eventually grew and remissions proved to be
transient. The authors suspected this may have been due to inefficient
d i s t r i b u t i o no fa n t i b o d yi nt h et u m o r bed. Additionally, these studies
required large quantities of antibodies to achieve the therapeutic effect
in vivo. Poor penetration of large antibody molecules through the BBB
could also account for their low or transient therapeutic effects. A few
studies have been successful in designing single-chain antibody
fragments (scFv) with specific high affinity binding for EGFRvIII
[23,24]. For example, Schmidt et al., demonstrated that genetic fusion
of scFv 14E1 with truncated form of Pseudomonas exotoxin A
drastically reduced metastases of Renca-EGFRvIII cells and number of
Renca-EGFR pulmonary tumor nodules in mice [25]. Thus, a
decrease in the size of therapeutic antibodies along with the
development of a new approach to deliver them to poorly accessible
CNS tumors may help to overcome the existing difficulties.
In recent years, mesenchymal stem cells (MSC) have been under
intense investigation as vehicles for targeted therapies to solid tumors.
MSCs are relatively easy to isolate and expand in vitro. They possess
natural tropism for the tumor and are able to migrate toward the
tumor after systemic, intra-arterial or distant from tumor sites injections
[26,27]. Genetic engineering of MSCs with therapeutic proteins has
been shown to prolong the survival of animals [27–31]. Recently, it has
been shown that both MSCs [32] and neural stem cells [33] can be
modified to secrete therapeutic antibodies, which can successfully
target xenograft tumors. MSCs were found to survive better in tumor
e n v i r o n m e n ti nc o m p a r i s o nw i t hn o r m a lb r a i nt i s s u e .D e s p i t et h i s ,i t
has been shown that the number of inoculated MSCs in the tumor
declines over the time [31]. It has also been shown that the therapeutic
effect depends on the proportion of MSCs in the tumor [34], and it was
suggested that several injections of MSCs might be required to achieve
a prolonged therapeutic effect [35]. Therefore, the approach to
increase the retention or homing of MSC in the tumors is warranted.
Moreover, the modification of MSCs with antibodies might become a
new strategy to deliver these therapeutic molecules which poorly
penetrate the BBB. The combination of antibody-directed targeting to
a specific cell population and the natural tropism of MSCs to tumor
holds the promise in that respect. Recently, we demonstrated the
feasibility of genetic modification of hMSCs to express scFv EGFRvIII
(hMSC-scFvEGFRvIII) on the cell surface in order to enhance their
targeting to EGFRvIII expressing tumors [36]. In this study we
investigated whether hMSC-scFvEGFRvIII possess the enhanced
properties to achieve enhanced retention in EGFRvIII expressing glial
tumor. Most importantly, we evaluated the therapeutic response, in
particular the growth of U87-EGFRvIII glioma cell in vitro and in vivo,
upon exposure to hMSC-scFvEGFRvIII.
Results
Effect of MSCs expressing scFvEGFRvIII on the growth of
U87-EGFRvIII cells in vitro
We evaluated the effect of hMSC on the growth of U87 cells in
co-culture experiments. hMSCs and hMSC-scFvEGFRvIII (i.e.
MSCs expressing scFv EGFRvIII on the cell surface) were added at
different ratios to CFDA SE labeled U87wt or U87EGFRvIII
gliomacellsandanalyzed fivedayslater.Weobserved nochangesin
proliferation of U87wt cells in co-culture with control or
scFvEGFRvIII modified hMSC. The ratio of mean fluorescent
intensity (MFI) of U87wt cells co-cultured with hMSC-scFv to that
with control hMSCs was equal to 0.98 in three independent
experiments. In contrast, U87-EGFRvIII cells responded by delay
of growth in co-culture with control hMSCs (190658% versus
106636% for U87wt glioma cells). This effect was seen only at 10:1
ratio of hMSCs to U87 glioma cells, however, the difference did not
reach statistical significance (Figure 1A). Nevertheless, the delay of
growth of U87-EGFRvIII cells was further enhanced in co-culture
with scFvEGFRvIII modified hMSCs (Figure 1B). The ratio of MFI
of U87-EGFRvIII cells co-cultured with hMSC-scFvEGFRvIII to
the MFI of the cells co-cultured with control hMSCs was 1.6,
suggesting that this delay in the growth of U87-EGFRvIII cells was
due to specific interaction of scFvEGFRvIII with U87-EGFRvIII.
In a separate set of experiments, we also evaluated if modification of
hMSCs with scFvEGFRvIII influenced their proliferative potential.
There was no statistical difference in the percentage of the BrdU
positive cells between control and hMSC-scFvEGFRvIII cells
pulsed with BrdU (4.860.95 vs. 5.360.4, respectively, p=0.4),
thus indicating a similar rate of proliferation of scFvEGFRvIII
modified and control hMSCs in vitro (Fig. S1).
Because we observed a delay in the growth of U87-EGFRvIII
glioma cells co-cultured with hMSC-scFvEGFRvIII, we hypoth-
esized that this effect might be mediated through changes in the
activity of downstream signaling molecules, in particular, pAkt.
Recently, the PI3K pathway was deemed as a dominant pathway
in glioma cells expressing high levels of EGFRvIII [37]. In our
experiments, GFP positive U87-EGFRvIII glioma cells were co-
cultured with control hMSCs or hMSC-scFvEGFRvIII for
48 hours. Glioma cells were sorted from the cell mixture based
on GFP expression and subjected to gel electrophoresis and
Western Blot analysis. Figure 1C shows the decrease in pAkt in
U87-EGFRvIII glioma cells co-cultured with hMSC. However,
the down-regulation of pAkt was most apparent in glioma cells co-
cultured with hMSC-scFvEGFRvIII cells. No visible effect of co-
culture of hMSCs on pAkt expression was observed in U87wt cells.
These data are consistent with the growth characteristics of U87wt
and U87-EGFRvIII cells in the presence of control and
scFvEGFRvIII modified hMSCs. Recently, Huang and co-authors
found that the EGFRvIII receptor cross-activates c-Met signaling
pathway [37]. In separate set of experiments, we evaluated the
activation of c-Met downstream signaling molecule STAT3 in
U87-EGFRvIII cells co-cultured with control or scFvEGFRvIII
modified hMSCs. We found that activation of STAT3 is
suppressed in U87-EGFRvIII glioma cells co-cultured with
hMSC-scFvEGFRvIII, but not control hMSCs or U87-EGFRvIII
alone (Fig. S2A). It is important to note that STAT3 also controls
cell growth and apoptosis. Therefore, down-regulation of pSTAT3
in these cells might be also partially responsible for this decrease in
the growth of U87-EGFRvIII in presence of modified hMSCs.
Interestingly, no significant change in the expression of EGFRvIII
was detected in U87-EGFRvIII cells co-cultured with hMSC-
scFvEGFRvIII (Fig. S2B). It is possible that decreased activation of
downstream molecules Akt and STAT3 is the result of decreased
autophosphorylation of the receptor itself.
Effect of scFvEGFRvIII modification on the retention of
hMSC in the tumor
In order to quantify the number of hMSCs within the tumor,
hMSCs were nucleofected with a plasmid encoding firefly
Genetically Modified hMSC
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of cells stably incorporating the luciferase gene. In vitro, luciferase
assay demonstrated that control and scFvEGFRvIII modified
hMSCs expressed equal amounts of luciferase (Figure 2A). We
performed titration of hMSCs expressing luciferase to estimate the
sensitivity of this assay and to determine the feasibility of its use for
in vivo experiments. We found that hMSCs counts as low as 8,000
could be detected in the tumor homogenized in 1 ml of the buffer
(Figure 2B).
We then injected 2610
6 hMSCs or hMSC-scFvEGFRvIII
alone, into the right flank of athymic mice and confirmed that
hMSCs themselves did not form tumors three weeks after
injection (data not shown). Next, we investigated the influence
of scFvEGFRvIII modification of hMSC on their retention in
EGFRvIII expressing tumors in vivo.F o rt h i s ,U 8 7 - E G F R v I I I
glioma cells were injected alone, or with control hMSCs or
hMSC-scFvEGFRvIII. On day 24, the tumors were excised,
weighed and homogenized in a lysis buffer. The luciferase
activity was measured in 10 ml of cleared supernatant. The total
luciferase activity in the tumor sample (e.g. number of the stem
cells present in the whole tumor) was recalculated by
multiplying luciferase activity in 10 ml to the total volume of
homogenate. Compared to flank tumors injected with control
hMSCs, tumors injected with scFvEGFRvIII modified hMSCs
displayed significantly increased luciferase activity (3.8 times
more) (Figure 2C). No luciferase activity was detected in the
control tumors injected with PBS. Assuming that luciferase
activity in hMSC in vitro corresponds to that in vivo,i ta p p e a r s
that flank tumors co-injected with 2610
6 hMSC-scFvEGFRvIII
retain approximately the same number of the cells on day 24,
whereas the number of control hMSCs is significantly
decreased. It is unclear at this point if scFvEGFRvIII interaction
with EGFRvIII on the surface of U87 cells promotes hMSCs
survival and/or proliferation within the tumor. This will be the
subject of further investigations.
In order to visualize our quantitative findings, in a separate
experiment, U87-EGFRvIII glioma cells expressing GFP and
hMSCs expressing RFP were injected in to the right flank. After 3
weeks, the flank tumors were excised, flash frozen and freshly
prepared 10 mm tissue sections were analyzed using fluorescent
microscopy. Figure 2D(i) shows the GFP expressing glioma tumor
cells in the presence of control hMSC expressing RFP (Figure 2D
(ii)) or hMSC-EGFRvIII expressing RFP (Figure 3D (iii)) within
the tumor bed. Representative picture out of 18 images captured
from each block is shown. In accordance with our quantitative
luciferase data, we observed a significantly higher presence of
hMSC-scFvEGFRvIII (red fluorescence) in the tumor compared
to control hMSCs. hMSCs were evenly distributed through the
tumor and had an appearance of cellular islands rather than single
hMSCs.
Figure 1. Modified hMSC-scFvEGFRvIII specifically delay the growth of U87-EGFRvIII glioma cells in vitro and down-regulate the
pAkt expression. A- CFDA SE labeled U87wt or U87-EGFRvIII GFP negative glioma cells were co-cultured with control hMSCs for 5 days. The change
in the U87 cells fluorescence was evaluated by the flow cytometry and is presented as MFI, % of control (U87 cells cultured without hMSCs). Data of
three independent experiments are summarized and presented as mean 6 SD. B- CFDA SE labeled U87wt or U87-EGFRvIII GFP negative glioma cells
were co-cultured with control and scFvEGFRvIII modified hMSC. The changes in the U87 cell fluorescence (e.g. growth) were tracked by flow
cytometry and expressed as MFI. The ratio of MFI of glioma cells co-cultured with hMSC-scFv to that with control hMSCs confirms the specific
response. Data of three independent experiments are shown and presented as mean 6 SD, * p,0.01. C- U87 cells expressing GFP and hMSC were co-
cultured at equal ratio for 48 hours. The U87wt and U87-EGFRvIII cells were sorted out based on their GFP expression and cell pellets were processed
for gel electrophoresis and Western Blot analysis. The pAkt and total Akt in cell lysates were detected using primary antibodies and developed with
secondary antibodies conjugated with HRP. Representative blot of two independent experiments is shown.
doi:10.1371/journal.pone.0009750.g001
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tumor growth in in vivo models
In order to confirm our in vitro finding of delayed growth of
U87-EGFRvIII glioma cells co-cultured with hMSC-scFvEGFR-
vIII, we performed several flank experiments.
In the first set of experiments, we studied the growth of s.c. flank
xenografts after co-injection of U87-EGFRvIII glioma cells with
hMSCs in athymic mice. Figure 3A shows staining of paraffin
embedded tumor sections either with isotype control (left panel) or
anti-EGFRvIII antibody (right panel), and confirms that flank
tumors maintained expression of U87EGFRvIII. Two weeks
following injection, tumors became measurable and tumor volume
was assessed every other day for the next 10 days. We observed a
significant delay in U87-EGFRvIII flank tumor growth in the
presence of hMSC-scFvEGFRvIII (n=8, p,0.05) by day 5. This
growth clearly was not appreciated in either of the controls groups
(Figure 3B). This disparity became more apparent with the
progression of tumor growth. Tumor volume in the hMSC-
scFvEGFRvIII group was approximately half the size of control
tumors by the day 24 (p,0.05).
In a second set of experiments, we examined if hMSC-scFv
could delay the growth of established s.c. flank U87-EGFRvIII
tumors in athymic mice. After 1 week of growth, flank tumors
reached a volume of 3667m m
3 and received one of the following:
(i) PBS (control); (ii) 1610
6 of control hMSCs; (iii) 1610
6 of
hMSC-scFvEGFRvIII. One week following injection of hMSCs,
the measurements of tumor volume were taken for the next 2
weeks and on day 28 the animals were sacrificed. Similar to the
data in co-injection experiment described above, the U87-
EGFRvIII flank tumors injected with hMSC-scFvEGFRvIII were
1.7 times smaller than tumors in the control (PBS) group (p=0.03,
n=6) or tumors injected with control hMSCs (p=0.05, n=6)
(326679 vs 5426220 vs 5556267 mm
3 respectively) at the end of
experiment (Figure 3C).
Figure 2. hMSC-scFvEGFRvIII presence in U87-EGFRvIII flank xenografts in athymic mice. A. hMSCs-scFv and control hMSCs were
nucleofected with pGL4.14 plasmid encoding luciferase gene and stable population was selected with hygromycin. Control and scFvEGFRvIII
expressing hMSC cells show equal expression of luciferase. Data presented as mean 6 SD, n=3. B. Titration of hMSC expressing luciferase. Sensitivity
of assay. C. Presence of hMSC-vector and hMSCscFvEGFRvIII in the s.c. flank U87-EGFRvIII xenograft at day 25 either alone or after co-injection of
control hMSC- vector or hMSC-scFvEGFRvIII cells (n=8 in each group). Luciferase assay. Data presented as mean 6 SD, * p,0.05. D. Microphotograph
of 10 mm tissue sections from s.c. xenograft of (i) GFP expressing U87-EGFRvIII cells alone and either (ii) with control hMSC-vector or (iii) hMSC-
scFvEGFRvIII cells at day 21. Arrows indicate the presence of hMSC expressing RFP.
doi:10.1371/journal.pone.0009750.g002
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an intracranial model of U87-EGFRvIII glioma
In order to confirm our findings in s.c. flank xenografts model,
we investigated the survival of animals injected intracranially with
1610
5 U87-EGFRvIII alone or co-injected with 1610
5 hMSCs.
Figure 4A shows the survival curve. By day 27, only 17% and 42%
of the animals survived in control group and in animals co-injected
with control hMSCs, respectively. On the other hand, we observed
100% of survival in the animals injected with hMSC-scFvEGFR-
vIII. However, during week 5 (days 28 through 34), the survival of
animals in hMSCs groups dropped drastically. Only one animal in
control U87-EGFRvIII group lasted to the day 33. Pair-wise
comparisons showed a significant difference in survival between
the control (U87-EGFRvIII) group and those injected either with
control hMSC (p,0.05, chi-square 5.32) or hMSC-scFvEGFRvIII
(p,0.001, chi-square 19.03). The median survival of control
animals or those injected with control hMSCs and hMSC-
scFvEGFRvIII was 25, 27 and 29 days, respectively.
Keeping in mind that the initial number of injected hMSC-
scFvEGFRvIII may not be sufficient to control the growth of
exponentially growing tumor cells, we implanted an additional
3610
5 hMSCs into the brain tumors two weeks after the initial
injection of 1610
5 U87-EGFRvIII and 1610
5 hMSCs and
evaluated the survival of these animals (Figure 4B). The survival
of the animals injected with hMSC-scFvEGFRvIII was increased
in comparison to controls (p=0.002, chi-square 121.24). The
median survival of animals in control group or injected with
control hMSCs and hMSC-scFvEGFRvIII was 29, 30.5 and 37
days, respectively. It is notable that the median survival in the
group which received additional injection of hMSC-scFvEGFR-
vIII was extended over the group of animals without an additional
injection, suggesting that hMSC expressing scFvEGFRvIII exert
therapeutic efficacy on established intracranial tumors in vivo.
In order to evaluate the distribution of hMSCs within a brain
tumor, tissues were flash frozen and cut into 10 mm sections for
analysis. We observed significantly more robust presence of
hMSC-scFvEGFRvIII in the U87-EGFRvIII expressing brain
tumor than control hMSCs (Figure 4C). These data corresponded
to our findings in the flank xenografts.
Since MSCs are known to secrete pro-angiogenic factors, we
evaluated if the significant retention of hMSCs expressing
scFvEGFRvIII in the tumor tissue promoted an increase in tumor
Figure 3. The effect of hMSC-scFvEGFRvIII on the growth of U87-EGFRvIII flank xenografts in athymic mice. A- Fixed paraffin
embedded section from the flank U87-EGFRvIII xenografts were stained with anti-EGFRvIII mAb L8A4. Left panel is a section stained with isotype
control mIgG. Right panel shows the expression of EGFRvIII in the tissues which was revealed with secondary antibodies conjugated with HRP. B-
U87-EGFRvIII glioma cells alone or with equal amount of either control hMSC-vector or hMSC-scFvEGFRvIII (n=8 in each group) were injected s.c. in
the right flank and grew until became measurable for 14 days. The volume measurements were taken every other day for next 10 days. Data
presented as mean 6 SD, * p,0.05. C- U87-EGFRvIII glioma cells were injected s.c. in the right flank. After one week, PBS, control hMSCs or hMSC-
scFvEGFRvIII (n=6 in each group) (1610
6 cells in 100 ml of PBS) were injected in the middle of the tumor and grown for another week, after which the
tumor volume measurements were taken every other day for the next 14 days. Data presented as mean 6 SD, * p,0.05.
doi:10.1371/journal.pone.0009750.g003
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number of the CD31 positive blood vessels in tumors with hMSC-
scFvEGFRvIII. In fact, we saw a lower number of CD31 positive
blood vessels in both groups which received control hMSCs and
hMSC-scFvEGFRvIII in comparison with a control group (73%
and 61 % of control respectively, p,0.001). It also worth
mentioning that we observed more prominent vascularization in
brain tumors compared to flank xenografts (data not shown)
Finally, we investigated if the inhibition of pAkt which we
observed in vitro is also sustained in vivo. Four week brain tumors
were excised and strained through the 70 mm meshworks. GFP
positive U87-EGFRvIII cells were sorted and analyzed by gel-
electrophoresis and Western Blot for pAkt and total Akt
expression. We found no difference in total Akt between the
groups. However, pAkt was down-regulated by 28% in glioma
cells co-injected with hMSC-scFvEGFRvIII. No difference in pAkt
expression in glioma cells was observed between control and
control hMSCs group (Figure 5B). Thus, these data are in
agreement with the delay of the growth observed in U87-
EGFRvIII tumors in the presence of hMSC-scFvEGFRvIII and
an increase in survival of these animals. It is also consistent with
our microscopy findings which show that hMSC expressing
scFvEGFRvIII present in tumor are in touch with only a fraction
of glioma cells within the tumor.
Discussion
Our previous study demonstrated that hMSCs can be
genetically engineered to express scFvEGFRvIII on the cell
surface and show improved binding with EGFRvIII expressing
U87 glioma cells [36]. In this study, we investigated if genetically
modified hMSCs expressing scFvEGFRvIII on their surface show
an increased retention in EGFRvIII expressing experimental glial
tumors and whether these cells can modify tumor growth through
antibody single-chain fragment-antigen interaction.
Here, we demonstrated that scFvEGFRvIII expressing hMSCs
were retained in U87-EGFRvIII xenografts approximately four
times better than control hMSCs. Our quantitative data are in a
strong agreement with microscopy analysis of tissue sections from
both flank xenografts and intracranial brain tumors, showing
significant presence of hMSC-scFvEGFRvIII within the tumor
mass in comparison with control hMSCs. Thus, genetic modifi-
cation of hMSCs with small antibody fragments to tumor specific
antigens opens the window for improvements in stem cell based
therapies of cancers overall.
In this study, we investigated if scFvEGFRvIII expressing
hMSCs could also influence the growth of U87 glioma cells
expressing EGFRvIII in vitro. Interestingly, we found that both
control hMSCs and hMSC-scFvEGFRvIII did not influence the
growth of U87wt cells. However, hMSC-scFvEGFRvIII delayed
the growth of U87-EGFRvIII glioma cells about 1.6 times more in
comparison with control hMSCs. We attribute this effect to the
interaction of scFvEGFRvIII expressed on the surface of hMSCs
with EGFRvIII expressed by the glioma cells. In this respect,
Sampson and co-authors demonstrated that a single intratumoral
injection of murine antibody Y10, which recognizes EGFRvIII,
significantly increased the median survival of animals with brain
Figure 4. hMSC-scFvEGFRvIII extend the survival of U87-EGFRvIII glioma in an intracranial model. A. U87-EGFRvIII cells alone (1610
5)o r
with equal amount of control or scFvEGFRvIII expressing hMSCs (n=12 per group) were inoculated in the right hemisphere of athymic mice. Survival
of the animals was recorded until last animal died. B. U87-EGFRvIII cells alone (1610
5) (n=13) or with equal amount of control (n=10) or scFvEGFRvIII
expressing hMSCs (n=11) were inoculated in the right hemisphere of athymic mice. Animals received an additional 3610
5 of control or hMSC-
scFvEGFRvIII intratumoral inoculation at 2 weeks and the survival of the animals was recorded. C. Microphotograph of 10 mm tissue sections from 4
week brain tumors (i) GFP expressing U87-EGFRvIII cells alone and either (ii) with control hMSC-vector or (iii) hMSC-scFvEGFRvIII cells. Arrows indicate
the presence of hMSC expressing RFP.
doi:10.1371/journal.pone.0009750.g004
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specifically recognizes U87 expressing EGFRvIII, was able to
inhibit the growth of xenografts in a dose dependent manner, but
not U87wt flank xenograft tumors [38]. Moreover, the significant
inhibition of EGFRvIII expressing brain tumors in the intracranial
model was observed after systemic injection of mAb806 [22].
We found that the delay in the growth of U87-EGFRvIII cells in
co-culture with hMSC-scFvEGFRvIII is mediated in part through
down-regulation of pAkt in U87 cells. We also observed the down-
regulation of pAkt in brain tumor samples. The down-regulation
of pAkt in vitro was greater than in vivo. This is consistent with the
fact that in vitro, most U87-EGFRvIII glioma cells are in intimate
contact with hMSC-scFvEGFRvIII. In vivo, however, we observed
a patchy pattern of distribution of hMSC-scFvEGFRvIII in the
tumor. This suggests that only a fraction of U87-EGFRvIII glioma
cells were in contact with the stem cells. Phospho-Akt executes its
role in tumorgenesis through inhibition of apoptosis and mediation
of proliferation. It has been shown that GBMs expressing
EGFRvIII demonstrate increased growth and invasiveness mostly
through the PI3K/pAkt [37]. Huang and co-authors also found
that c-Met signaling pathway was cross-activated in EGFRvIII
over-expressing cells [37]. In our studies, we also observed a
decrease in activation STAT3 in U87-EGFRvIII cells co-cultured
with hMSCs-EGFRvIII, suggesting that multiple pathways might
be involved in the regulation of growth in these cells. No
significant changes in the expression of the EGFRvIII receptor
were observed in our studies. It is possible that decreased
activation of downstream molecules Akt and STAT3 is caused
by decreased autophosphorylation of the receptor itself. Mishima
and co-authors investigated the effect of a monoclonal anti-
EGFRvIII antibody (mAb 806) in vivo. They demonstrated that
treatment with mAb 806 resulted in a significant decrease in
autophosphorylation of EGFRvIII and downstream molecule Bcl-
XL, whereas the receptor level was only slightly decreased. The
authors concluded that this particular antibody affected the
intrinsic signaling function of the EGFRvIII receptor [22].
Interestingly, in our in vitro study, pAkt was also down-regulated
in U87-EGFRvIII by control hMSCs although to a lesser extent
than by hMSC-scFvEGFRvIII. This was not observed in vivo.I t
has been shown that hMSCs were able to down-regulate pAkt in
Kaposi’s sarcoma cells when co-cultured, as well as in primary
endothelial cells and neonatal cardiac myocytes, and this effect
required direct cell-cell contact [39].
To support our findings in vitro, we evaluated the growth of U87-
EGFRvIII s.c. flank xenografts alone or in the presence of control
or scFvEGFRvIII expressing hMSCs. Similar to our in vitro data,
flank xenografts grew at significantly slower rate in the presence of
hMSCs expressing scFv EGFRvIII than control tumors. This
Figure 5. Brain tumor vascularization in the presence of hMSC-scFvEGFRvIII and pAkt expression. A. Tissue section (10 mm) from flash
frozen brains carrying tumors were stained for mouse CD31, (a) negative control, U87-EGFRvIII GFP expressing tumor; (b) CD31 positive blood vessels
in U87-EGFRvIII GFP expressing tumor; (c) CD31 positive blood vessels in U87-EGFRvIII GFP expressing tumor co-injected with control hMSCs; (d)
CD31 positive blood vessels in U87-EGFRvIII GFP expressing tumor co-injected with hMSC-scFvEGFRvIII. Arrows show CD31 positive blood vessels.
The number of CD31 positive blood vessels was calculated in each field (n=18) (magnification 106) and data summarized in the graph. * p,0.001. B.
Expression of pAkt in glioma cells sorted from 4 week old tumors established with U87-EGFRvIII alone or with control or scFvEGFRvIII expressing
hMSCs. Representative Western Blot from two independent experiments is shown.
doi:10.1371/journal.pone.0009750.g005
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glioma cells and hMSCs were co-injected or hMSCs injected into
established tumor. It is worth noting that the effect of hMSC-
scFvEGFRvIII on established EGFRvIII tumor was dependent on
the initial tumor size. When hMSCs-scFv were injected in larger
tumors, they did not influence xenograft growth. This could be
due to the fact that the proportion of injected hMSCs to the tumor
mass is relatively low. With this in mind, repeated inoculations of
hMSCs in the tumors and possibly at different locations might be
necessary for efficient therapy of large established tumors. Other
authors have made the observation that the therapeutic effect of
MSCs is dependent on the proportion of hMSCs to the tumor cells
[34]. A recent study by Kim and co-authors also suggested that
repeated administration of MSC-stTRAIL in established glioma
tumor with a control of cell number, interval between injection
and expression of the therapeutic protein will be necessary for
clinical application [35]. We observed no effect of control hMSCs
on the growth of flank or brain tumors. These data are in an
agreement with recent study demonstrating the absence of the
growth-promoting effect of MSCs on glial brain tumors [31],
which was shown in other types of tumors [40,41]. Of note, while
there is clear heterogeneity in EGFRvIII expression in brain
tumors, the enhanced benefit of targeting modified hMSC should
result in a bystander effect to cells which do not express EGFRvIII.
The prolonged association of these MSC with the tumor may
translate in the prolonged release of secreted therapeutics in the
tumor environment.
In our study the survival of animals with intracranial of U87-
EGFRvIII glioma co-injected with hMSC-scFvEGFRvIII was
significantly improved compared to the control groups. However,
the survival was prolonged only by one week. An additional injection
of hMSC-scFvEGFRvIII in the already growing tumor further
prolonged the median survival of the animals. Thesedata suggestthat
tumor-eradicating therapy will have to take advantage of the
substantial presence of hMSC-scFvEGFRvIII within the tumor in
comparison with unmodified hMSCs. Interestingly, we found a lower
density of CD31 positive blood vessels in the brain tumors from the
animals that received control hMSCs and hMSC-scFvEGFRvIII.
This was also consistent with the increase in animal survival in these
groups incomparison with controlsand can be explained by the delay
of tumor growth and therefore lower density of the CD31 positive
blood vessels at given time points. The literature on the effect of
MSCs on neovascularization of the tumors, however, is controversial.
It has been reported that MSCs are the source of soluble factors
promoting angiogenesis [42,43]. However, it also has been reported
t h a tM S C sa r ea b l et od e c r e a s ea n g i o g e n e s i si nm e l a n o m at u m o r
xenografts model [44], but not affect the angiogenesis in rat
malignant glioma [45]. The effect of MSCs on angiogenesis therefore
likely depends on a particular tumor type.
In conclusion, we demonstrate for the first time that hMSCs
modified to express scFv to EGFRvIII on their surface displayed
prolonged retention in EGFRvIII expressing glioma. This was
confirmed in vivo in flank and intracranial xenografts models.
Moreover, we found that hMSC-scFvEGFRvIII posses therapeu-
tic effect by delaying growth of tumors and prolonging the survival
of the animals with intracranial brain tumors. However, this
‘‘bonus’’ property of hMSC-scFvEGFRvIII is not sufficient to use
these cells as monotherapy. Taking in consideration the increased
presence of hMSCs expressing scFvEGFRvIII within the tumor,
the modification of these stem cells with a therapeutic gene might
significantly boost their therapeutic potential. The use of
genetically modified hMSC with scFv to EGFRvIII and other
tumor specific antigens might eliminate the need of repetitive
inoculation of hMSC to achieve the prolonged and desired
therapeutic effect. Such an approach offers an attractive prospect
for gene therapy applications and should be further explored in
preclinical tumor models.
Materials and Methods
Ethics Statement
All studies were reviewed and approved by the Institutional
Animal Care Committee at the University of Chicago.
Reagents
MEM and MEM alpha media, antibiotic-antimycotic were
purchased from Invitrogen (Carlsbad, CA). The premium select
fetal bovine serum (FBS) was obtained from Atlanta Biologicals
(Lawrenceville, GA). Trypsin-EDTA was purchased from Media-
tech Inc. (Manassas, VA). The geneticin (G418), 5-bromo-29-
deoxyuridine (BrdU) and anti-actin antibodies werepurchased from
Sigma (St. Louis, MO). The fluorescent tracer carboxyfluorescein
diacetate, succinimidyl ester (CFDA SE) was purchased from
Molecular Probes (Eugene, OR). BrdU flow kit was obtained from
BD Biosciences (San Diego, CA). M-Per mammalian protein
extraction buffer, Halt protease inhibitors cocktail and phosphatase
inhibitor are from Thermo Scientific (Rockford, IL). The Tris-HCl
gel and PVDF membrane, ImmunStar WesternC were purchased
from Bio-Rad, (Hercules, CA). Antibodies to total and pAkt were
purchased from Cell Signaling Technology (Danvers, MA).
Antibodies to phospho STAT3 and total STAT3 were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA). Secondary anti-
mouse and anti-rabbit antibodies conjugated peroxidase were
purchased from Chemicon Intl. (Temicula, CA). The rat anti-
mouse CD31 antibodies were obtained from Santa Cruz Biotech-
nology (Santa Cruz, CA) and secondary anti-rat antibodies
conjugated with DyLight 649 were obtained from Jackson
ImmunoResearch Laboratories (West Grove, PA). The monoclonal
antibody (mAb) L8A4 is generous gift of Dr. Bigner (Duke
University Medical Center, Durham, NC). The plasmid pGL4.14
encoding luciferase was purchased from Promega (Madison, WI).
Cell Culture
hMSC were grown in MEM alpha media supplemented with
antibiotic-antimycotic and 10% premium select FBS. Media was
replaced every 48 hours. Cells were re-plated using 0.25% trypsin-
EDTA after they reached 80% of confluency. The U87 glioma
cells expressing EGFRvIII were grown in MEM media supple-
mented with 10% heat inactivated FBS and 200 mg/ml of G418.
Genetic Modification of hMSC
hMSCs were modified to express scFv to EGFRvIII as previously
described [36]. Briefly, hMSCs were nucleofected either with empty
vector(control hMSCs) orwitha plasmid encoding scFvEGFRvIII-
PDGFRtransmembranedomainfusionusingAMAXA technology.
The stable population of cells expressing scFvEGFRvIII was
selected with G418 and further enriched using cell sorting. The
control hMSCs and hMSC-scFvEGFRvIII were infected with
retrovirus encoding red fluorescent protein (RFP) and selected with
puromycin. For luciferase expression, hMSCs were nucleofected
with pGL4.14 plasmid encoding luciferase gene and stable
population of cells that incorporated the luciferase gene was
selected with hygromycin.
Proliferation assay
GFP negative U87wt and U87-EGFRvIII cells were labeled with
2.5 mM SFDA SE fluorescent tracer and immediately seeded on 6
well plates at density of 1610
5 cells/well. The control hMSC or
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ratios: 1:0; 1:0.1; 1:1 and 1:10. Culture media was changed every
48 hours. After 5 days, the cells were collected using trypsin-EDTA
and SFDA SE labeled U87 cells were analyzed by flow cytometry.
Mean fluorescence intensity (MFI) was estimated for each group of
co-cultured cells. In order to demonstrate the specificity of the effect
hMSC-scFvEGFRvIII on the growth of U87-EGFRvIII cells, data
were presented as ratio of MFI for U87 cells co-cultured with hMSC-
scFvEGFRvIII to that with control hMSCs.
BrdU Assay
Stable populations of control and scFvEGFRvIII expressing
hMSCs were pulsed with 10 mM BrdU for 2 hours. Cells were
treated with only BrdU solvent as a control for background binding of
anti-BrdU-FITC mAb with cells. Cells were stained for incorporated
BrdU according to manufacturer’s recommendation. Briefly, cells
were collected and fixed with fixation/perm solution. Washed cells
were treated with DNase for 1 hour at 37uC and after washing were
subsequently stained with anti-BrdU-FITC antibodies. Percentage of
BrdU positive cells was determined by flow cytometry.
Western Blotting
U87wt or U87-EGFRvIII cells expressing green fluorescent
protein (GFP) were co-cultured either with control hMSCs or
hMSC-scFvEGFRvIII at the ratio 1:1 for 48 hours. Co-cultured
cells were dissociated using trypsin-EDTA and sorted to collect
only GFP positive U87 cells. To analyze the U87-EGFRvIII cells
from the brain tumors, the tumors were strained through 70 mm
meshworks and sorted to collect GFP positive U87 cells. The cell
pellets were lysed using the M-Per mammalian protein extraction
buffer containing Halt protease inhibitors cocktail and phospha-
tase inhibitor. Samples were applied to 10% Tris-HCl gel at
40 mg/lane and resolved under reducing conditions. After the
transfer of proteins to PVDF membrane and blocking with 2%
non-fat dry milk, the membrane was stained subsequently with
anti-pAKT, total Akt, anti-pSTAT3, total STAT3, anti-EGFRvIII
and anti-beta actin antibodies, followed by appropriate secondary
antibody conjugated with peroxidase. ImmunStar WesternC was
used to develop the reaction. Images were captured using the Bio-
Rad’s ChemiDoc Imaging System (Hercules, CA).
Immunocytochemistry
Flash frozen flank and brain tumor tissues were cut to a
thickness of 10 mm. Tissue sections were fixed with 220uC
methanol and stained for mouse CD31 using rat monoclonal
antibodies at concentration 5 mg/ml. The bound antibodies were
revealed by goat anti-rat DyLight649 secondary antibodies at
concentration 10 mg/ml. After repeated washing to remove
unbound antibodies with PBS containing 0.05% Tween 20, cover
slips were rinsed once in water and mounted in fluoromount-G
(Southern Biotech, Birmingham, Alabama) containing 1 mg/ml
DAPI. Positive FITC staining was analyzed using Olympus IX70
inverted microscope and MetaMorph software.
For EGFRvIII staining, xenograft tissue was fixed with 4%
paraformaldehyde. Paraffin-embedded tissue was cut to 6 mm and
antigen retrieval was performed using 0.01 M citrate buffer at
pH 6.0 for 30 minutes in the oven. Tissue sections were stained
with 10 mg/ml of L8A4 mAb and revealed with secondary anti-
mouse antibody conjugated with HRP.
Animal Studies
All animals were maintained and cared for in accordance with
the Institutional Animal Care and Use Committee protocol and
regulations. The animals used in the experiments were 6–8 weeks
old male athymic nu/nu mice from Harlan Laboratories
(Indianapolis, IN). All animals were housed in a pathogen free
facility at The University of Chicago. Mice were anaesthetized
with an intraperitoneal injection of ketamine hydrochloride
(25 mg/ml)/xylazine (2.5 mg/ml) cocktail.
For s.c. xenografts, mice were injected in the right flank with
2610
6 of U87-EGFRvIII cells in 100 ml of PBS or in a mixture
with equal amount of control hMSCs or hMSCscFv. In a separate
set of experiments, PBS, control hMSCs, or hMSC-scFvEGFRvIII
were injected into the tumor in growing U87-EGFRvIII flank
xenografts. When tumors became measurable, tumor dimensions
were estimated using slide caliber and the volume was calculated
according the previously reported formula (L x W x H)/2 [46].
To establish intracranial tumors, a midline cranial incision was
made and a right-sided burr hole was placed 2 mm lateral to the
sagittal sinus and approximately 2 mm superior to the lambda.
Animals were positioned in stereotactic frame and a Hamilton
needle was then inserted into the burr hole and advanced 3 mm.
Intracranial penetration was followed by injection of 1610
5 cells in
2.5 ml of sterile PBS. In one set of experiments, U87-EGFRvIII
cells were injected alone or in mixture with 1610
5 MSC-vector or
hMSC-scFvEGFRvIII. In another set of experiments, animals
received additional injection of 2.5 ml PBS or 3610
5 of hMSCs in
the same volume (control hMSCs or hMSC-scFvEGFRvIII). All
mice were followed to assess survival and upon death, the brains
were harvested for microscopic analysis.
Statistical analysis
The differences between groups were evaluated by calculating
Student’s t-value or one way ANOVA with post-hoc comparison
Tukey’s test. For the in vivo survival data, a Kaplan-Meier survival
analysis was used and statistical analysis was performed using a
Log rank test. P,0.05 was considered statistically significant.
Supporting Information
Figure S1 Comparison of control hMSCs and scFvEGFRvIII
modified MSCs with respect to the rate of proliferation in vitro.
Control and scFvEGFRvIII modified MSCs were labeled with
BrdU for 2 hours at 370C. After the fixation/permeabilization
and treatment with DNase, control and BrdU treated cells were
stained anti-BrdU-FITC antibody and analyzed by flow cytom-
etry. Data is presented as percentage of BrdU positive cells (mean
6 SD). Summary of two independent experiments is shown.
Found at: doi:10.1371/journal.pone.0009750.s001 (0.12 MB TIF)
Figure S2 A. Phosphorylation of STAT3 in U87-EGFRvIII cells
after co-culture with hMSC-scFvEGFRvIII. U87-EGFRvIII cells
expressing GFP and hMSCs were co-cultured at equal ratio for
48 hours. The U87-EGFRvIII cells were sorted out based on their
GFP expression and cell pellets were processed for gel electro-
phoresis and Western Blot analysis. The phosphorylated STAT3
(phoso STAT3), total STAT3 and beta actin in cell lysates were
detected using primary antibodies and developed with secondary
antibodies conjugated with HRP. Representative blots of two
independent experiments are shown. B. Expression EGFRvIII in
U87-EGFRvIII cells after co-culture with hMSC-scFvEGFRvIII.
U87 cells expressing GFP and hMSCs were co-cultured at equal
ratio for 48 hours. The U87wt and U87-EGFRvIII cells were
sorted out based on their GFP expression and cell pellets were
processed for gel electrophoresis and Western Blot analysis. The
EGFRvIII and beta actin in cell lysates were detected using
primary antibodies and developed with secondary antibodies
Genetically Modified hMSC
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experiments is shown.
Found at: doi:10.1371/journal.pone.0009750.s002 (1.41 MB TIF)
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